Lexaria Bioscience

LEXX75

High Growth

$3.26arrow_drop_up1.54%$0.04

High Growth

Penny Stock

LEXX75

$3.26

arrow_drop_up1.54%$0.04

High Growth

Penny Stock

Performance History

Key Stats
Open	$3.27
Prev. Close	$3.26
EPS	-0.44
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$51.54M
PE Ratio	-

	LOW	HIGH
Day Range	3.21	3.34
52 Week Range	0.85	6.85

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.44

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Lexaria Bioscience (LEXX)

Lexaria Bioscience Corp. (LEXX) is a biosciences company that specializes in drug delivery platforms. The company's primary focus is on developing innovative methods to enhance the delivery of various drugs and compounds. Lexaria's goal is to provide more efficient and effective delivery options for pharmaceutical, nutraceutical, and cannabis-based products.

One of Lexaria's key technologies is its proprietary DehydraTECH platform, which enhances the delivery of drugs through the gastrointestinal tract. DehydraTECH utilizes a patented process to optimize the delivery of molecules, increasing their bioavailability and absorption rates. This technology has the potential to revolutionize the way drugs are administered and improve patient outcomes.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Christopher A. Bunka
Headquarters: Kelowna
Employees: 7
Exchange: NASDAQ

Keep an eye on Lexaria Bioscience

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Lexaria Bioscience's (LEXX) price per share?

The current price per share for Lexaria Bioscience (LEXX) is $3.2. The stock has seen a price change of $0.05 recently, indicating a 1.55% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Lexaria Bioscience (LEXX)?

For Lexaria Bioscience (LEXX), the 52-week high is $6.85, which is 109.49% from the current price. The 52-week low is $0.85, the current price is 284.69% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Lexaria Bioscience (LEXX) a growth stock?

Lexaria Bioscience (LEXX) has shown an average price growth of 0.41% over the past three years. It has received a score of 24 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Lexaria Bioscience as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Lexaria Bioscience (LEXX) stock price performance year to date (YTD)?

As of the latest data, Lexaria Bioscience (LEXX) has a year-to-date price change of 153.48%. Over the past month, the stock has experienced a price change of 2.83%. Over the last three months, the change has been 10.1%. Over the past six months, the figure is -3.83%.

help

Is Lexaria Bioscience (LEXX) a profitable company?

Lexaria Bioscience (LEXX) has a net income of -$6.71M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 86.07% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.07K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $194.71K. Operating income is noted at -$6.53M. Furthermore, the EBITDA is -$4.53M.

help

What is the market capitalization of Lexaria Bioscience (LEXX)?

Lexaria Bioscience (LEXX) has a market capitalization of $51.54M. The average daily trading volume is 85.38K, indicating the stock's liquidity and investor engagement.